A phase IIIb, multi-center, open-label, expanded access study of EVERolimus (RAD001)in combination with EXemestane in post-menopausal women with EStrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer - EVEREXES

Trial Profile

A phase IIIb, multi-center, open-label, expanded access study of EVERolimus (RAD001)in combination with EXemestane in post-menopausal women with EStrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer - EVEREXES

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Expanded access
  • Acronyms EVEREXES
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2015 Interim results presented at the 38th Annual San Antonio Breast Cancer Symposium (n =232).
    • 02 Jun 2015 Interim results (n=251) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 21 Mar 2014 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top